文献速递艾滋病与性传播感染

HIV感染者持续病毒抑制下免疫恢复程度与癌症风险

Risk of Cancer in People With HIV Experiencing Varying Degrees of Immune Recovery With Sustained Virological Suppression on Antiretroviral Treatment for More Than 2 Years: An International, Multicenter, Observational Cohort.
PubMed 文献 · Clin Infect Dis · 2025-01-01

时间更新CD4计数较高与总体癌症风险降低相关,CD4 350-499、500-749、≥750 cells/µL较<350 cells/µL的调整发病率比分别为0.45、0.30、0.26。

要点

  • 持续病毒抑制>2年者中,免疫恢复差仍与癌症发生率显著升高相关。
  • CD4≥750 cells/µL者总体癌症风险约为<350 cells/µL者的0.26倍。
  • 无论基线CD4最低值如何,较高时间更新CD4均与癌症风险降低相关。

核心结论

  • 尽管ART持续病毒抑制超过2年,免疫恢复较差者癌症发生率显著更高。

研究设计与样本

  • 国际多中心观察性队列,纳入D:A:D和RESPOND协作中1999年12月至2022年12月间ART持续病毒抑制≥2年的HIV感染者。

主要发现

  • 中位随访6.2年发生1933例癌症,总发病率为6.43/1000人年(95%CI 6.15-6.73)。
  • 时间更新CD4 350-499 cells/µL者总体癌症调整发病率比为0.45(95%CI 0.39-0.51),500-749 cells/µL为0.30(95%CI 0.27-0.34),≥750 cells/µL为0.26(95%CI 0.23-0.30),均与<350 cells/µL比较,P<.0001。
  • 无论ART前最低CD4计数如何,较高时间更新CD4计数均与所有癌症风险显著降低相关,且ART前最低CD4较高者风险更低。

关键数值与推荐

  • 时间更新CD4计数350-499 cells/µL较<350 cells/µL的总体癌症调整发病率比为0.45(95%CI 0.39-0.51)。
  • 时间更新CD4计数500-749 cells/µL较<350 cells/µL的总体癌症调整发病率比为0.30(95%CI 0.27-0.34)。
  • 时间更新CD4计数≥750 cells/µL较<350 cells/µL的总体癌症调整发病率比为0.26(95%CI 0.23-0.30),P<.0001。

临床怎么用

  • 研究结果强调早期HIV诊断和ART启动的重要性。
  • 对免疫恢复较差者应考虑适当的癌症筛查策略。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The impact of long-term virological suppression (VS) and CD4 count recovery on non-AIDS-defining cancers (NADCs) is unclear. We determined whether poor immune recovery was associated with incident cancer risk in people with human immunodeficiency virus (HIV) with VS. METHODS: Participants from the Data-Collection on Adverse Effects of Anti-HIV Drugs (D:A:D) and International Cohort Consortium of Infectious Disease (RESPOND) collaborations in Europe and Australia who achieved ≥2 years of VS on antiretroviral therapy (ART) between December 1999 and December 2022 were included. Follow-up was from baseline (date of VS for 2 years) until the earliest of a first cancer event, virological failure, final follow-up, or administrative censoring date. Multivariable Poisson regression was used to assess associations between cancer incidence (overall, AIDS-defining cancer, NADC, infection-related cancer, infection-unrelated cancer) and time-updated CD4 count stratified by pre-ART nadir CD4 counts. RESULTS: Overall, 48 343 people with VS were included (median [interquartile range] baseline age, 43 years [37-50]; CD4 count, 540 cells/µL [380-730]; nadir CD4 count, 245 cells/µL [121-394]; 74% male). There were 1933 incident cancers (median follow-up, 6.2 years [2.9-9.5]; incidence rate [IR], 6.43; 95% confidence interval [CI]: 6.15-6.73/1000 person-years). Higher time-updated CD4 count was associated with a reduced risk of overall cancer (adjusted incidence rate ratio for time-updated CD4 count 350-499 cells/µL: 0.45 [95% CI: 0.39-0.51]; 500-749 cells/µL: 0.30 [95% CI: 0.27-0.34]; and ≥750 cells/µL: 0.26 [95% CI: 0.23-0.30] vs <350 cells/µL; P < .0001). There was a significant reduction in all cancer risk by higher time-updated CD4 count, regardless of nadir CD4 count, with higher pre-ART nadir CD4 count exhibiting lower risk. CONCLUSIONS: Despite VS on ART for more than 2 years, people with poorer immune recovery experienced a significantly higher incidence of cancer. This highlights the importance of early HIV diagnosis and ART initiation, and appropriate cancer screening strategies for those with poor immune recovery.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Han WM, Ryom L, Sabin CA, et al. Risk of Cancer in People With HIV Experiencing Varying Degrees of Immune Recovery With Sustained Virological Suppression on Antiretroviral Treatment for More Than 2 Years: An International, Multicenter, Observational Cohort. Clin Infect Dis. 2025. PMID: 40368374. doi:10.1093/cid/ciaf248

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。